Uranyl binary and ternary chelates of tenoxicam Synthesis, spectroscopic and thermal characterization of ternary chelates of tenoxicam and alanine with transition metals.

[1]  M. Zayed,et al.  Synthesis and thermal characterization of new ternary chelates of piroxicam and tenoxicam with glycine and DL-phenylalanine and some transition metals. , 2006, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[2]  G. Mohamed.  Structural and thermal characterization of ternary complexes of piroxicam and alanine with transition metals: uranyl binary and ternary complexes of piroxicam. Spectroscopic characterization and properties of metal complexes. , 2005, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[3]  G. Mohamed,et al.  Study of the ternary complexes of copper with salicylidene-2- aminothiophenol and some amino acids in the solid state , 2004 .

[4]  G. Mohamed,et al.  Synthesis, investigation and spectroscopic characterization of piroxicam ternary complexes of Fe(II), Fe(III), Co(II), Ni(II), Cu(II) and Zn(II) with glycine and DL-phenylalanine. , 2004, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[5]  G. Gehad,et al.  Preparation and spectroscopic characterisation of metal complexes of piroxicam , 2004 .

[6]  M. Zayed,et al.  Structure investigation, spectral, thermal, X-ray and mass characterization of piroxicam and its metal complexes. , 2004, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[7]  A. Orlandini,et al.  Speciation study of the anti-inflammatory drug tenoxicam (Htenox) with Cu(II): X-ray crystal structure of [Cu(tenox)(2)(py)(2)].EtOH. , 2003, Journal of inorganic biochemistry.

[8]  R. Cini,et al.  Synthesis, X-ray structural characterization and solution studies of metal complexes containing the anti-inflammatory drugs meloxicam and tenoxicam , 2003 .

[9]  S. Geib,et al.  Synthesis and characterization of a novel iron (III) silsesquioxane compound , 2003 .

[10]  P. A. Lay,et al.  Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized , 2002 .

[11]  M. N. Ponnuswamy,et al.  Synthesis of copper(II) and nickel(II) complexes using compartmental ligands: X-ray, electrochemical and magnetic studies , 2001 .

[12]  F. Caruso,et al.  PRECURSORS OF HEXA-AZAMACROCYCLES. SYNTHESIS AND X-RAY STRUCTURE OF 2,9-DIAMINOPHENANTHROLINEBISACETATE-Co(II) AND 6,6′-DIAMINOBIPYRIDINE-BISACETATE-M(II) (M = Ni, Cu) , 2001 .

[13]  L. Vlaev,et al.  Study on the kinetics of the isothermal decomposition of selenites from IIIB group of the periodic system , 2001 .

[14]  P. A. Lay,et al.  Syntheses and characterization of anti-inflammatory dinuclear and mononuclear zinc indomethacin complexes. Crystal structures of [Zn2(indomethacin)4(L)2] (L = N,N-dimethylacetamide, pyridine, 1-methyl-2-pyrrolidinone) and [Zn(indomethacin)2(L1)2] (L1 = ethanol, methanol). , 2000, Inorganic chemistry.

[15]  F. V. Meurs,et al.  Spectral and structural studies of iron(III), cobalt(II,III) and nickel(II) complexes of 2-pyridineformamide N(4)-methylthiosemicarbazone , 1999 .

[16]  M. Valko,et al.  Cyanamidonitrate–copper(II) complexes of imidazole ligands: X-ray crystallography and physical investigation , 1999 .

[17]  P. A. Lay,et al.  Anti-Inflammatory Dinuclear Copper(II) Complexes with Indomethacin. Synthesis, Magnetism and EPR Spectroscopy. Crystal Structure of the N,N-Dimethylformamide Adduct. , 1999, Inorganic chemistry.

[18]  F. Albert Cotton,et al.  Advanced Inorganic Chemistry , 1999 .

[19]  K. Thomas,et al.  Cis-facial coordination of bis(pyrid-2-ylmethyl)amine (bpma). Synthesis, structure and spectral behaviour of [Ni(bpma)2]2+ , 1998 .

[20]  M. Moustafa.  Spectrophotometric analysis, thermal analysis and gravimetric determination of some metal ions with oxime and Schiff's base derivatives of N-furoylphenylhydroxylamine , 1997 .

[21]  A. F. el Walily,et al.  Simultaneous determination of tenoxicam and 2-aminopyridine using derivative spectrophotometry and high-performance liquid chromatography. , 1997, Journal of pharmaceutical and biomedical analysis.

[22]  O. Atay,et al.  Quantitative Determination of Tenoxicam by Infrared Spectrophotometry , 1997 .

[23]  A. Bjorksten,et al.  Oral Tenoxicam for Peripheral Orthopaedic Surgery: A Pharmacokinetic Study , 1997, Anaesthesia and intensive care.

[24]  R. Butcher,et al.  The preparation and characterization of bis-chelated nickel(II) complexes of the 6-methylpyridine-2-carboxaldehyde Schiff bases of S-alkyldithiocarbazates and the X-ray crystal structure of the bis {S-methyl-β-N- (6-methylpyrid-2-yl)- methylenedithiocarbazato}nickel(II) complex , 1997 .

[25]  M. Tunçel,et al.  The Polarographic Determination of Tenoxicam in the Pharmaceutical Preparations , 1996 .

[26]  W. Radecka-Paryzek,et al.  The scandium(III) ion as a template for the synthesis of a hexaazaSchiff base macrocyclic ligand , 1995 .

[27]  E. Baran,et al.  Darstellung und Eigenschaften von Vanadyl(IV)-Saccharinat , 1993 .

[28]  C. Rossi,et al.  Metal complexes of the antiinflammatory drug piroxicam , 1990 .

[29]  J. Viré,et al.  Copper (II), Lead (II) and Cadmium (II) Complexes with the Antiinflammatory Drugs Piroxicam and Tenoxicam , 1989 .

[30]  S. El-khateeb,et al.  Analysis of Piroxicam Via Its Copper (Ii) and Iron (Iii) Complexes , 1989 .

[31]  J. Sorenson,et al.  Copper complexes offer a physiological approach to treatment of chronic diseases. , 1989, Progress in medicinal chemistry.

[32]  Colin Eaborn,et al.  Comprehensive Coordination Chemistry , 1988 .

[33]  J. P. Smith,et al.  Metal complexes of anti-inflammatory drugs. Part IV. Tenoxicam complexes of manganese(II), iron(III), cobalt(II), nickel(II) and copper(II) , 1987 .

[34]  J. P. Gonzalez,et al.  Tenoxicam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. , 1987, Drugs.

[35]  V. Moreno,et al.  Some new derivatives of Co(III) with uracil, uridine and pyrimidine nucleotides , 1987 .

[36]  J. Sorenson.  Inflammatory Diseases and Copper , 1982, Experimental Biology and Medicine.

[37]  David R. Williams,et al.  Metal-ligand complexes involved in rheumatoid arthritis—V: Formation constants for calcium(II)-, magnesium(II)- and copper(II)-salicylate and acetylsalicylate interactions☆ , 1978 .

[38]  David R. Williams,et al.  Metal-ligand complexes involved in rheumatoid arthritis—I: Justifications for copper administration☆ , 1978 .

[39]  David R. Williams,et al.  Metal-ligand complexes involved in rheumatoid arthritis—IV: Formation constant and species distribution considerations for copper(II) -cystinate, -oxidised penicillaminate and -oxidised glutathionate interactions and considerations of the action of penicillamine in vivo☆ , 1978 .

[40]  David R. Williams,et al.  Metal-ligand complexes involved in rheumatoid arthritis—II: Acidic drug-serum albumin-copper(II) interactions investigated using visible spectrophotometry and molecular filtration , 1978 .

[41]  John Aurie Dean,et al.  Lange's Handbook of Chemistry , 1978 .

[42]  J. Sorenson.  Copper chelates as possible active forms of the antiarthritic agents. , 1976, Journal of medicinal chemistry.

[43]  H. Willis,et al.  The infrared spectra of N-substituted sulphonamides , 1969 .

[44]  A. W. Coats,et al.  Kinetic Parameters from Thermogravimetric Data , 1964, Nature.